European Commission president Ursula von der Leyen announed on Monday (9 November) that the EU is about to sign a contract with Pfizer and BioNTech for up to 300 million doses of its experimental Covid-19 vaccine, after the companies found it to be more than 90 percent effective.
"Today is a great day for science and humanity," Pfizer's chairman Albert Bourla said on Monday (9 November), adding that the results from the late-stage trial of their potential vaccine have shown the initial ...
Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.
Already a member? LoginElena is EUobserver's editor-in-chief. She is from Spain and has studied journalism and new media in Spanish and Belgian universities. Previously she worked on European affairs at VoteWatch Europe and the Spanish news agency EFE.
Elena is EUobserver's editor-in-chief. She is from Spain and has studied journalism and new media in Spanish and Belgian universities. Previously she worked on European affairs at VoteWatch Europe and the Spanish news agency EFE.